The Tissue and Research Pathology Services (TARPS) is a newly proposed shared facility that serves as the central support for UPCI research programs needing tissue materials from patients at the University of Pittsburgh Medical Center (UPMC). The main objectives of TARPS are (1) to provide a mechanism to simplify and streamline the process of research tissue accrual and disbursement and (2) to provide efficient research pathology support services. The tissue accrual and disbursement function of TARPS has been in existence since 1991 as a small service facility, with a focus on genitourinary cancers. The resource has substantially expanded in the last 5 years and now procures and disburses tissue materials from patients with a diverse array of cancers, and provides support to major research projects such as the hmg Specialized Program Of Research Excellence (SPORE), Early Disease Research Network (EDRN)-related research efforts, and several other cancer research programs. Services provided by TARPS include (1) tissue and biological specimen procurement services, (2) research histology services, (3) annotated clinical data, and (4) the Tissue Micro-Array (TMA) facilities. Future efforts include development of procedures to molecularly profile tumors on a real time basis. TARPS plans to extend the development of its infrastructure already in place for cancers such as prostate and head and neck cmacers, to other areas such as gastrointestinal and pancreatic cancers, hematologic malignancies, and melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-21
Application #
7669419
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
21
Fiscal Year
2008
Total Cost
$215,396
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Liu, Zuqiang; Ge, Yan; Wang, Haiyan et al. (2018) Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9:4682

Showing the most recent 10 out of 1187 publications